IL89703A - Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof - Google Patents

Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof

Info

Publication number: IL89703A
Authority: IL; Israel
Prior art keywords: dna; ache; human; acetylcholinesterase; polynucleotide molecule
Prior art date: 1989-03-21

Application number

IL8970389A

Other languages

English (en)

Other versions

IL89703A0 (en

Inventor

Hermona Soreq

Haim Zakut

Original Assignee

Yissum Res Dev Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-21

Filing date

1989-03-21

Publication date

2001-10-31

1989-03-21 Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co

1989-03-21 Priority to IL8970389A priority Critical patent/IL89703A/en

1989-09-28 Publication of IL89703A0 publication Critical patent/IL89703A0/xx

1989-12-26 Priority to JP1338048A priority patent/JPH03195496A/ja

1989-12-27 Priority to CA002006744A priority patent/CA2006744A1/fr

1990-03-20 Priority to EP90105274A priority patent/EP0388906B1/fr

1990-03-20 Priority to DE69020018T priority patent/DE69020018T2/de

1990-03-20 Priority to AT90105274T priority patent/ATE123814T1/de

1990-03-21 Priority to CA002012720A priority patent/CA2012720A1/fr

1993-08-02 Priority to US08/111,314 priority patent/US5595903A/en

2001-10-31 Publication of IL89703A publication Critical patent/IL89703A/en

Links

101000801359 Homo sapiens Acetylcholinesterase Proteins 0.000 title claims abstract description 58
108091033319 polynucleotide Proteins 0.000 title claims description 19
239000002157 polynucleotide Substances 0.000 title claims description 19
102000040430 polynucleotide Human genes 0.000 title claims description 19
102000004190 Enzymes Human genes 0.000 title description 18
108090000790 Enzymes Proteins 0.000 title description 18
229940088598 enzyme Drugs 0.000 title description 18
239000013598 vector Substances 0.000 title description 7
239000012634 fragment Substances 0.000 claims abstract description 35
230000000694 effects Effects 0.000 claims abstract description 28
208000008784 apnea Diseases 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims abstract description 13
238000001356 surgical procedure Methods 0.000 claims abstract description 10
231100000572 poisoning Toxicity 0.000 claims abstract description 9
230000000607 poisoning effect Effects 0.000 claims abstract description 9
AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 claims abstract description 9
229940032712 succinylcholine Drugs 0.000 claims abstract description 9
239000000729 antidote Substances 0.000 claims abstract description 3
230000002265 prevention Effects 0.000 claims abstract 4
108010022752 Acetylcholinesterase Proteins 0.000 claims description 95
108090000623 proteins and genes Proteins 0.000 claims description 68
239000000523 sample Substances 0.000 claims description 67
238000009396 hybridization Methods 0.000 claims description 49
239000002299 complementary DNA Substances 0.000 claims description 48
108090000765 processed proteins & peptides Proteins 0.000 claims description 34
238000000034 method Methods 0.000 claims description 30
210000004027 cell Anatomy 0.000 claims description 19
102000004196 processed proteins & peptides Human genes 0.000 claims description 18
229920001184 polypeptide Polymers 0.000 claims description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
208000032839 leukemia Diseases 0.000 claims description 13
229940022698 acetylcholinesterase Drugs 0.000 claims description 12
230000002159 abnormal effect Effects 0.000 claims description 11
125000003275 alpha amino acid group Chemical group 0.000 claims description 11
239000013604 expression vector Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 8
102000012440 Acetylcholinesterase Human genes 0.000 claims description 6
239000003298 DNA probe Substances 0.000 claims description 6
230000002255 enzymatic effect Effects 0.000 claims description 6
210000000601 blood cell Anatomy 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims description 4
108020003215 DNA Probes Proteins 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 3
229940058344 antitrematodals organophosphorous compound Drugs 0.000 claims description 2
238000001962 electrophoresis Methods 0.000 claims description 2
210000003527 eukaryotic cell Anatomy 0.000 claims description 2
210000004962 mammalian cell Anatomy 0.000 claims description 2
210000000653 nervous system Anatomy 0.000 claims description 2
150000002903 organophosphorus compounds Chemical class 0.000 claims description 2
WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 claims 1
230000003343 megakaryocytopoietic effect Effects 0.000 claims 1
102100033639 Acetylcholinesterase Human genes 0.000 description 101
108020004414 DNA Proteins 0.000 description 95
108090000322 Cholinesterases Proteins 0.000 description 46
102000003914 Cholinesterases Human genes 0.000 description 41
206010028980 Neoplasm Diseases 0.000 description 33
238000003199 nucleic acid amplification method Methods 0.000 description 31
210000004556 brain Anatomy 0.000 description 25
230000003321 amplification Effects 0.000 description 23
230000001605 fetal effect Effects 0.000 description 21
210000001519 tissue Anatomy 0.000 description 20
239000002773 nucleotide Substances 0.000 description 19
125000003729 nucleotide group Chemical group 0.000 description 18
206010033128 Ovarian cancer Diseases 0.000 description 17
238000004458 analytical method Methods 0.000 description 17
210000000287 oocyte Anatomy 0.000 description 17
101150060184 ACHE gene Proteins 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 16
210000000349 chromosome Anatomy 0.000 description 16
150000001413 amino acids Chemical class 0.000 description 15
108020004999 messenger RNA Proteins 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
238000002105 Southern blotting Methods 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
210000004185 liver Anatomy 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
239000000758 substrate Substances 0.000 description 12
210000004227 basal ganglia Anatomy 0.000 description 11
210000005259 peripheral blood Anatomy 0.000 description 11
239000011886 peripheral blood Substances 0.000 description 11
108091028043 Nucleic acid sequence Proteins 0.000 description 10
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 10
238000002372 labelling Methods 0.000 description 10
229940046166 oligodeoxynucleotide Drugs 0.000 description 10
IOIMDJXKIMCMIG-UHFFFAOYSA-N Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)- Chemical compound CC(C)NP(=O)(NC(C)C)OP(=O)(NC(C)C)NC(C)C IOIMDJXKIMCMIG-UHFFFAOYSA-N 0.000 description 9
125000000539 amino acid group Chemical group 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
238000010186 staining Methods 0.000 description 9
108700020796 Oncogene Proteins 0.000 description 8
230000005856 abnormality Effects 0.000 description 8
238000007901 in situ hybridization Methods 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
230000004544 DNA amplification Effects 0.000 description 7
208000005374 Poisoning Diseases 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
230000003197 catalytic effect Effects 0.000 description 7
229940048961 cholinesterase Drugs 0.000 description 7
208000035475 disorder Diseases 0.000 description 7
230000007062 hydrolysis Effects 0.000 description 7
238000006460 hydrolysis reaction Methods 0.000 description 7
210000001672 ovary Anatomy 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
108020004635 Complementary DNA Proteins 0.000 description 6
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
108091034057 RNA (poly(A)) Proteins 0.000 description 6
241000269370 Xenopus <genus> Species 0.000 description 6
230000002950 deficient Effects 0.000 description 6
238000001514 detection method Methods 0.000 description 6
238000002955 isolation Methods 0.000 description 6
239000012528 membrane Substances 0.000 description 6
238000000424 optical density measurement Methods 0.000 description 6
238000012216 screening Methods 0.000 description 6
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 6
GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 5
102000004157 Hydrolases Human genes 0.000 description 5
108090000604 Hydrolases Proteins 0.000 description 5
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical class CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
230000004075 alteration Effects 0.000 description 5
230000000093 cytochemical effect Effects 0.000 description 5
208000018706 hematopoietic system disease Diseases 0.000 description 5
102000045310 human ACHE Human genes 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
230000035987 intoxication Effects 0.000 description 5
231100000566 intoxication Toxicity 0.000 description 5
238000000520 microinjection Methods 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 4
102000004308 Carboxylic Ester Hydrolases Human genes 0.000 description 4
108090000863 Carboxylic Ester Hydrolases Proteins 0.000 description 4
102100032404 Cholinesterase Human genes 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
101710134987 Esterase 6 Proteins 0.000 description 4
208000009774 Follicular Cyst Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
102000043276 Oncogene Human genes 0.000 description 4
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
101100371145 Woolly monkey sarcoma virus V-SIS gene Proteins 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
238000000246 agarose gel electrophoresis Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000034994 death Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
201000010099 disease Diseases 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
238000011002 quantification Methods 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
229910052709 silver Inorganic materials 0.000 description 4
239000004332 silver Substances 0.000 description 4
241000894007 species Species 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
206010000871 Acute monocytic leukaemia Diseases 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
108010053652 Butyrylcholinesterase Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
208000013544 Platelet disease Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229940124639 Selective inhibitor Drugs 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
230000032683 aging Effects 0.000 description 3
210000004958 brain cell Anatomy 0.000 description 3
210000005056 cell body Anatomy 0.000 description 3
230000001713 cholinergic effect Effects 0.000 description 3
239000000544 cholinesterase inhibitor Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
238000010835 comparative analysis Methods 0.000 description 3
239000002131 composite material Substances 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000003754 fetus Anatomy 0.000 description 3
229960005051 fluostigmine Drugs 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000002917 insecticide Substances 0.000 description 3
230000036244 malformation Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
150000002923 oximes Chemical group 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000002574 poison Substances 0.000 description 3
231100000614 poison Toxicity 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
238000011451 sequencing strategy Methods 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
108700021652 sis Genes Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
229940124596 AChE inhibitor Drugs 0.000 description 2
208000024320 Abnormal platelet count Diseases 0.000 description 2
241000251468 Actinopterygii Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010004433 Benign ovarian tumour Diseases 0.000 description 2
208000019838 Blood disease Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000252203 Clupea harengus Species 0.000 description 2
201000010374 Down Syndrome Diseases 0.000 description 2
101000943274 Homo sapiens Cholinesterase Proteins 0.000 description 2
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 2
210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108020005187 Oligonucleotide Probes Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical compound CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 description 2
102000009843 Thyroglobulin Human genes 0.000 description 2
206010044688 Trisomy 21 Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
206010046798 Uterine leiomyoma Diseases 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 2
208000020700 acute megakaryocytic leukemia Diseases 0.000 description 2
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
229960000396 atropine Drugs 0.000 description 2
238000000211 autoradiogram Methods 0.000 description 2
AWBGQVBMGBZGLS-UHFFFAOYSA-N butyrylthiocholine Chemical compound CCCC(=O)SCC[N+](C)(C)C AWBGQVBMGBZGLS-UHFFFAOYSA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000013461 design Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000007824 enzymatic assay Methods 0.000 description 2
230000006862 enzymatic digestion Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
229960005542 ethidium bromide Drugs 0.000 description 2
235000019688 fish Nutrition 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
208000014951 hematologic disease Diseases 0.000 description 2
210000003958 hematopoietic stem cell Anatomy 0.000 description 2
235000019514 herring Nutrition 0.000 description 2
210000003917 human chromosome Anatomy 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
238000012760 immunocytochemical staining Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
210000000715 neuromuscular junction Anatomy 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
201000008016 ovarian benign neoplasm Diseases 0.000 description 2
RLBIQVVOMOPOHC-UHFFFAOYSA-N parathion-methyl Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C=C1 RLBIQVVOMOPOHC-UHFFFAOYSA-N 0.000 description 2
-1 phosphoryl moiety Chemical group 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000002250 progressing effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
210000000225 synapse Anatomy 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
229960002175 thyroglobulin Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
101000801347 Bos taurus Acetylcholinesterase Proteins 0.000 description 1
101800001415 Bri23 peptide Proteins 0.000 description 1
102400000107 C-terminal peptide Human genes 0.000 description 1
101800000655 C-terminal peptide Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108010051152 Carboxylesterase Proteins 0.000 description 1
102000013392 Carboxylesterase Human genes 0.000 description 1
229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
206010009269 Cleft palate Diseases 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
208000001154 Dermoid Cyst Diseases 0.000 description 1
108700015884 Drosophila Est-6 Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
208000001951 Fetal Death Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010055690 Foetal death Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
241000244206 Nematoda Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091036407 Polyadenylation Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
241000251733 Tetronarce californica Species 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
241000269368 Xenopus laevis Species 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003491 array Methods 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
208000014759 blood platelet disease Diseases 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
101150062912 cct3 gene Proteins 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
231100000005 chromosome aberration Toxicity 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
101150112777 cue gene Proteins 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000020335 dealkylation Effects 0.000 description 1
238000006900 dealkylation reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
231100000479 fetal death Toxicity 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
238000002169 hydrotherapy Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
208000025113 myeloid leukemia Diseases 0.000 description 1
210000003643 myeloid progenitor cell Anatomy 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
201000010193 neural tube defect Diseases 0.000 description 1
208000002040 neurosyphilis Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
230000011164 ossification Effects 0.000 description 1
229960004623 paraoxon Drugs 0.000 description 1
WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 1
LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
108020004418 ribosomal RNA Proteins 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012764 semi-quantitative analysis Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
208000035581 susceptibility to neural tube defects Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
235000008979 vitamin B4 Nutrition 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Toxicology (AREA)
Diabetes (AREA)
Hematology (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

IL8970389A 1989-03-21 1989-03-21 Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof IL89703A (en)

Priority Applications (8)

Application Number	Priority Date	Filing Date	Title
IL8970389A IL89703A (en)	1989-03-21	1989-03-21	Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof
JP1338048A JPH03195496A (ja)	1989-03-21	1989-12-26	成長因子
CA002006744A CA2006744A1 (fr)	1989-03-21	1989-12-27	Acides nucleiques et polypeptides qu'ils encodent
EP90105274A EP0388906B1 (fr)	1989-03-21	1990-03-20	Cholinesterases humaines produites par génie génétique
DE69020018T DE69020018T2 (de)	1989-03-21	1990-03-20	Gentechnologische menschliche Cholinesterasen.
AT90105274T ATE123814T1 (de)	1989-03-21	1990-03-20	Gentechnologische menschliche cholinesterasen.
CA002012720A CA2012720A1 (fr)	1989-03-21	1990-03-21	Cholinesterases humaines produites par des procedes de genie genetique
US08/111,314 US5595903A (en)	1989-03-21	1993-08-02	Genetically engineered human acetylcholinesterase

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL8970389A IL89703A (en)	1989-03-21	1989-03-21	Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof

Publications (2)

Publication Number	Publication Date
IL89703A0 IL89703A0 (en)	1989-09-28
IL89703A true IL89703A (en)	2001-10-31

Family

ID=11059811

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8970389A IL89703A (en)	1989-03-21	1989-03-21	Polynucleotide encoding human acetylcholinesterase, vectors comprising said polynucleotide, cells transformed by said vectors, enzyme produced by said transformed cell, and uses thereof

Country Status (7)

Country	Link
US (1)	US5595903A (fr)
EP (1)	EP0388906B1 (fr)
JP (1)	JPH03195496A (fr)
AT (1)	ATE123814T1 (fr)
CA (1)	CA2012720A1 (fr)
DE (1)	DE69020018T2 (fr)
IL (1)	IL89703A (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5248604A (en) *	1991-07-22	1993-09-28	Bio-Technology General Corp.	Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
US6025183A (en) *	1994-02-28	2000-02-15	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Transgenic animal assay system for anti-cholinesterase substances
US6326139B1 (en) *	1996-01-11	2001-12-04	Yissum Research Development Company Of Hebrew University Of Jerusalem	Method of screening for genetic predisposition to anticholinesterase therapy
US6441388B1 (en)	1998-10-13	2002-08-27	Rio Grande Medical Technologies, Inc.	Methods and apparatus for spectroscopic calibration model transfer
US7098037B2 (en)	1998-10-13	2006-08-29	Inlight Solutions, Inc.	Accommodating subject and instrument variations in spectroscopic determinations
US6157041A (en) *	1998-10-13	2000-12-05	Rio Grande Medical Technologies, Inc.	Methods and apparatus for tailoring spectroscopic calibration models
US6770799B2 (en) *	2000-03-17	2004-08-03	Thompson Boyce Plant Res	Expression of recombinant human acetylcholinesterase in transgenic plants
IL161354A0 (en) *	2004-04-13	2004-09-27	Yissum Res Dev Co	NOVEL AChE VARIANTS
US9062321B2 (en)	2004-12-01	2015-06-23	Arizona Board Of Regents On Behalf Of Arizona State University	Codon-optimized polynucleotides encoding human butyrylcholinesterase and plant expression systems therof
US7741431B2 (en) *	2005-02-01	2010-06-22	The United States Of America As Represented By The Secretary Of The Army	Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
US20090220587A1 (en) *	2005-02-01	2009-09-03	United State Army	Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
WO2009139905A2 (fr) *	2008-05-16	2009-11-19	Nektar Therapeutics	Conjugués d'un groupe fonctionnel cholinestérase et d'un polymère
AU2010340358B2 (en)	2009-12-21	2014-07-24	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
US20130071394A1 (en)	2011-09-16	2013-03-21	John K. Troyer	Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
PL240561B1 (pl)	2017-10-09	2022-05-02	Gdanski Univ Medyczny	Wektory DNA zdolne do transformacji i integracji z chromosomem Leishmania tarentolae zawierające gen kodujący butyrylocholinoesterazę BChE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA84232B (en) *	1983-01-21	1984-11-28	Bio Response Inc	Isolation and culture of mammalian cells secreting acetylcholinesterase and recovering of acetylcholinesterase therefrom
IL75553A (en) *	1985-06-18	1993-07-08	Yeda Res & Dev	Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
US5248604A (en) *	1991-07-22	1993-09-28	Bio-Technology General Corp.	Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof

1989
- 1989-03-21 IL IL8970389A patent/IL89703A/en not_active IP Right Cessation
- 1989-12-26 JP JP1338048A patent/JPH03195496A/ja active Pending
1990
- 1990-03-20 AT AT90105274T patent/ATE123814T1/de not_active IP Right Cessation
- 1990-03-20 EP EP90105274A patent/EP0388906B1/fr not_active Expired - Lifetime
- 1990-03-20 DE DE69020018T patent/DE69020018T2/de not_active Expired - Fee Related
- 1990-03-21 CA CA002012720A patent/CA2012720A1/fr not_active Abandoned
1993
- 1993-08-02 US US08/111,314 patent/US5595903A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0388906B1 (fr)	1995-06-14
CA2012720A1 (fr)	1990-09-21
US5595903A (en)	1997-01-21
DE69020018T2 (de)	1995-10-26
EP0388906A2 (fr)	1990-09-26
IL89703A0 (en)	1989-09-28
JPH03195496A (ja)	1991-08-27
ATE123814T1 (de)	1995-06-15
DE69020018D1 (de)	1995-07-20
EP0388906A3 (fr)	1991-04-17

Publication	Publication Date	Title
US5595903A (en)	1997-01-21	Genetically engineered human acetylcholinesterase
US20050196833A1 (en)	2005-09-08	Cyclic GMP-binding, cyclic GMP-specific phosphodiesterase materials and methods
DE69131482T2 (de)	1999-11-18	Phosphotyrosin phosphatase als neuer rezeptor-typ
US5215909A (en)	1993-06-01	Human cholinesterase genes
Gnatt et al.	1990	Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors
EP0206200B1 (fr)	1992-09-23	Protéines d'origine humaine du type cholinestérase et leur production
US5538886A (en)	1996-07-23	Receptor-type phosphotyrosine phosphatase-alpha
DE69530261T2 (de)	2004-01-22	Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
US5888794A (en)	1999-03-30	Receptor-type phosphotyrosine phosphatase-alpha
US5891700A (en)	1999-04-06	Receptor-type phosphotyrosine phosphatase-γ
WO1994018308A1 (fr)	1994-08-18	NOUVELLE PHOSPHOTYROSINE PHOSPHATASE-β DE TYPE RECEPTEUR
AU5443394A (en)	1994-05-09	A new class of rptpases: their structural domains and ligands
US6682905B1 (en)	2004-01-27	Receptor-type phosphotyrosine phosphatase-alpha
US7108994B2 (en)	2006-09-19	Receptor-type phosphotyrosine phosphatase-alpha
Soreq et al.	1987	Molecular biology approach to the expression and properties of mammalian cholinesterases
JP2001512007A (ja)	2001-08-21	Ｚｇｇｂｐ１、１型双極性感情障害に関与する新規ペプチド、配列及びその使用
JP2002540795A (ja)	2002-12-03	Ｄｓｐ−４二重特異性ｍａｐキナーゼホスファターゼ
Hermona	1987	Molecular Cloning of Human Gene (s) Directing the Synthesis of Nervous System Cholinesterases
Soreq	0	IN HUMAN BRAIN TISSUES
Soreq	1990	Molecular Biological Studies on the Biogenesis of Human Cholinesterases in vivo and as Directed by Cloned Cholinesterase DNA Sequences
HK1013427B (en)	2001-12-07	Cyclic gmp-binding, cyclic gmp-specific phosphodiesterase materials and methods
HK1013427C (en)	2001-12-07	Cyclic gmp-binding, cyclic gmp-specific phosphodiesterase materials and methods

Legal Events

Date	Code	Title	Description
2003-06-24	KB	Patent renewed
2008-01-06	MM9K	Patent not in force due to non-payment of renewal fees